Status:
RECRUITING
Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions:
Multiple Myeloma
Diagnosis
Eligibility:
All Genders
18+ years
Brief Summary
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxi...
Detailed Description
This is an observational prospective cohort study aimed at assessing the efficacy of different types of thromboprophylaxis in MM patients; the setting is the GIMEMA network of the Italian haematologic...
Eligibility Criteria
Inclusion
- Age equal to or greater than 18 years of age.
- New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group
- First active treatment for MM started after recruitment in the study
- Signed informed consent
Exclusion
- Patients having had thrombosis within 6 months before diagnosis of MM
- Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs)
- Ongoing first active treatment for MM initiated before the starting of the study.
Key Trial Info
Start Date :
March 10 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2030
Estimated Enrollment :
736 Patients enrolled
Trial Details
Trial ID
NCT06028087
Start Date
March 10 2025
End Date
March 1 2030
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione Policlinico Universitario A. Gemelli IRCCS UOC Servizio e DH di Ematologia
Roma, Italy